Nick Gassick
Analyst
Leerink Partners
Equibles does not estimate personal net worth.
About Nick Gassick
Nick Gassick is recorded as Analyst at Leerink Partners. Nick Gassick has spoken on 3 earnings calls across 1 company, most recently for Vir Biotechnology, Inc. on May 7, 2025. The companies whose calls Nick Gassick spoke on are classified in the Healthcare sector.
Nick Gassick on recent calls
“Maybe first on HBV, how should we think about your expectations heading into the 24-week GOFF treatment data for MARCH and EASL? You know, what are you hoping to see from a functional cure standpoint relative to the end of treatment data we got at ASLD?”
“Maybe first on the HDV Phase III trial design, just thinking about the target patient population. Are you going to be focusing on both cirrhotic and non-cirrhotic?”
“Just first on HDV, could you provide a little more color around how large the market opportunity is in HDV currently? And also, could you discuss what a possible accelerated approval pathway could look like for Tabeva Bart and Alebsiran in HDV?”
Affiliation history
-
Leerink Partners
Analyst
Transcript header (unverified)
Current